2 Nov

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

Merck has become the first covid-19 therapeutic or vaccine owner to strike a deal with the MPP. Here are the most important takeaways from the agreement.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth